Dihydroartemisinin: A Potential Natural Anticancer Drug

被引:159
作者
Dai, Xiaoshuo [1 ]
Zhang, Xiaoyan [1 ,2 ,3 ]
Chen, Wei [1 ,2 ]
Chen, Yihuan [1 ]
Zhang, Qiushuang [1 ]
Mo, Saijun [1 ,2 ]
Lu, Jing [1 ,2 ,3 ]
机构
[1] Zhengzhou Univ, Dept Pathophysiol, Sch Basic Med Sci, 100 Sci Rd, Zhengzhou 450001, Henan, Peoples R China
[2] Zhengzhou Univ, Collaborat Innovat Ctr Henan Prov Canc Chemopreve, Zhengzhou 450001, Henan, Peoples R China
[3] Zhengzhou Univ, State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou 450052, Henan, Peoples R China
来源
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES | 2021年 / 17卷 / 02期
关键词
Dihydroartemisinin; Cancer; Proliferation; Apoptosis; Combination medication; Clinical trail;
D O I
10.7150/ijbs.50364
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dihydroartemisinin (DHA) is an active metabolite of artemisinin and its derivatives (ARTs), and it is an effective clinical drug widely used to treat malaria. Recently, the anticancer activity of DHA has attracted increasing attention. Nevertheless, there is no systematic summary on the anticancer effects of DHA. Notably, studies have shown that DHA exerts anticancer effects through various molecular mechanisms, such as inhibiting proliferation, inducing apoptosis, inhibiting tumor metastasis and angiogenesis, promoting immune function, inducing autophagy and endoplasmic reticulum (ER) stress. In this review, we comprehensively summarized the latest progress regarding the anticancer activities of DHA in cancer. Importantly, the underlying anticancer molecular mechanisms and pharmacological effects of DHA in vitro and in vivo are the focus of our attention. Interestingly, new methods to improve the solubility and bioavailability of DHA are discussed, which greatly enhance its anticancer efficacy. Remarkably, DHA has synergistic anti-tumor effects with a variety of clinical drugs, and preclinical and clinical studies provide stronger evidence of its anticancer potential. Moreover, this article also gives suggestions for further research on the anticancer effects of DHA. Thus, we hope to provide a strong theoretical support for DHA as an anticancer drug.
引用
收藏
页码:603 / 622
页数:20
相关论文
共 118 条
[51]   Dihydroartemisinin represses esophageal cancer glycolysis by down-regulating pyruvate kinase M2 [J].
Li, Shumin ;
Huang, Peng ;
Gan, Junqing ;
Ling, Xiaodong ;
Du, Xiaoxue ;
Liao, Yuanyu ;
Li, Lisha ;
Meng, Yu ;
Li, Yanjing ;
Bai, Yuxian .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 854 :232-239
[52]   Dihydroarteannuin ameliorates lupus symptom of BXSB mice by inhibiting production of TNF-alpha and blocking the signaling pathway NF-kappa B translocation [J].
Li, Wei-Dong ;
Dong, Yan-Jun ;
Tu, You-You ;
Lin, Zhi-Bin .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2006, 6 (08) :1243-1250
[53]   Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein [J].
Li, Xiaoguang ;
Ba, Qian ;
Liu, Yanling ;
Yue, Qingxi ;
Chen, Peizhan ;
Li, Jingquan ;
Zhang, Haibing ;
Ying, Hao ;
Ding, Qiurong ;
Song, Haiyun ;
Liu, Hong ;
Zhang, Ruiwen ;
Wang, Hui .
CELL DISCOVERY, 2017, 3
[54]   Dihydroartemisinin Accentuates the Anti-Tumor Effects of Photodynamic Therapy via Inactivation of NF-κB in Eca109 and Ec9706 Esophageal Cancer Cells [J].
Li, Yan Jing ;
Zhou, Jian Hua ;
Du, Xiao Xue ;
Jia, De Xin ;
Wu, Chun Long ;
Huang, Peng ;
Han, Yu ;
Sui, Hong ;
Wei, Xiao Li ;
Liu, Lei ;
Yuan, Heng Heng ;
Zhang, Ting Ting ;
Zhang, Wen Jie ;
Xie, Rui ;
Lang, Xiao Hui ;
Liu, Tao ;
Jiang, Cai Ling ;
Wang, Li Ying ;
Bai, Yu Xian .
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2014, 33 (05) :1527-1536
[55]   Dihydroartemisinin Increases the Sensitivity of Photodynamic Therapy Via NF-κB/HIF-1α/VEGF Pathway in Esophageal Cancer Cell in vitro and in vivo [J].
Li, Yanjing ;
Sui, Hong ;
Jiang, Cailing ;
Li, Shumin ;
Han, Yu ;
Huang, Peng ;
Du, Xiaoxue ;
Du, Jingwen ;
Bai, Yuxian .
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 48 (05) :2035-2045
[56]   Dihydroartemisinin suppresses pancreatic cancer cells via a microRNA-mRNA regulatory network [J].
Li, Yilong ;
Wang, Yongwei ;
Kong, Rui ;
Xue, Dongbo ;
Pan, Shangha ;
Chen, Hua ;
Sun, Bei .
ONCOTARGET, 2016, 7 (38) :62460-62473
[57]  
Liao K, 2014, INT J CLIN EXP PATHO, V7, P8684
[58]   Dihydroartemisinin Induces Endothelial Cell Autophagy through Suppression of the Akt/mTOR Pathway [J].
Liu, Jing ;
Ren, Yanjun ;
Hou, Yinglong ;
Zhang, Caiqing ;
Wang, Bei ;
Li, Xiaorui ;
Sun, Rong ;
Liu, Ju .
JOURNAL OF CANCER, 2019, 10 (24) :6057-6064
[59]   Development of R8 modified epirubicin-dihydroartemisinin liposomes for treatment of non-small-cell lung cancer [J].
Liu, Jing-Jing ;
Tang, Wei ;
Fu, Min ;
Gong, Xiao-Qing ;
Kong, Liang ;
Yao, Xue-Min ;
Jing, Ming ;
Cai, Fu-Yi ;
Li, Xue-Tao ;
Ju, Rui-Jun .
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2019, 47 (01) :1947-1960
[60]   Rapamycin promotes the anticancer action of dihydroartemisinin in breast cancer MDA-MB-231 cells by regulating expression of Atg7 and DAPK [J].
Liu, Qiujun ;
Zhou, Xianyao ;
Li, Chuan ;
Zhang, Xuemei ;
Li, Chang Long .
ONCOLOGY LETTERS, 2018, 15 (04) :5781-5786